New Jersey Will Demonstrate Its Life Sciences Prowess

New Jersey will showcase more than 20 organizations, including top companies, universities, trade associations, state government and Choose New Jersey, Inc. at the New Jersey Pavilion at the world’s largest biotechnology conference, Bio International 2016. From June 7-9, the New Jersey delegation will meet with European, Canadian and Australian business executives from life science-based organizations interested in learning what makes the State a perfect place to start or relocate their bio-related firm.

“New Jersey is an undisputed leader in life sciences,” says Michele Brown, president and CEO of Choose New Jersey, Inc. “Our great State consistently ranks among the nation’s top states in every critical category, including talent, industry support and innovation. BIO 2016 gives us the strategic opportunity to present New Jersey’s assets to an international community of biopharmaceutical executives.”

New Jersey is home to 14 of the world’s top biopharmaceutical companies, more than 400 biotech companies, 12 of the world’s top R&D companies, 4 medical schools and 13 teaching hospitals. In 2015, 53 percent of FDA approvals came from companies with a New Jersey footprint, and 26 percent of the products in the State’s drug pipeline are in Phase III trials, compared to 16 percent for the industry as a whole. New Jersey’s world-class universities have a long history of discovering unique technologies and collaboration with the private sector.

“Companies that don’t already have headquarters or facilities in New Jersey look to us when they are ready to commercialize their products in the US,” says Brown. “The State has the world’s highest concentration of scientists and engineers, as well as the highest concentration of development and commercialization talent in the country. The availability of an experienced workforce, combined with its other assets for life sciences companies, make New Jersey a natural choice for companies that are looking to bring their products to market.”

Choose New Jersey is partnering with BioNJ, the New Jersey Business Action Center (BAC) and the New Jersey Economic Development Authority (NJEDA) to sponsor the 1,500-square-foot New Jersey Pavilion at Moscone Center. Companies represented in the Pavilion include: Bell Works; Ferring Pharmaceuticals; Novartis Pharmaceuticals; Janssen Pharmaceutical Companies of Johnson & Johnson; Zoetis; Helsinn; Sills Cummis & Gross; Amicus Therapeutics; BLS & Co.; Cepter Biopartners; and, Vivo Bio Tech Ltd.

The strength of New Jersey’s hospitals and research universities will be represented by: Hackensack University Medical Center (HackensackUMC); New Jersey Institute of Technology (NJIT); Princeton University; Rowan University; Stevens Institute of Technology; and, Rutgers, The State University of New Jersey.

“We’re eager to showcase New Jersey’s dynamic life sciences ecosystem in the New Jersey Pavilion in partnership with Choose New Jersey, including the unprecedented innovation coming from the State – coupled with an unparalleled talent pool,” says Debbie Hart, president and CEO, BioNJ. Choose New Jersey, the Healthcare Institute of New Jersey (HINJ), New Brunswick Development Corporation (DEVCO) and Jones Lang LaSalle (JLL) also are sponsoring a by-invitation-only reception where they will discuss the strategic advantages of a New Jersey location with a select group of company decision makers. Last year’s event was attended by more than 100 guests, including more than 50 executives considering a move to New Jersey.

“As the lead sponsor of its reception at the BIO International Convention, HINJ is pleased to partner again with Choose New Jersey in its efforts to promote the State’s world-class life sciences innovation ecosystem,” says Dean J. Paranicas, President and CEO, HealthCare Institute of New Jersey.

Choose New Jersey, BAC and NJEDA also are scheduling private business meetings with company executives interested in exploring a New Jersey location.

Related Articles: